IBEC researchers uncover strategy to reduce chemotherapy side effects
Researchers at IBEC and IDIBELL have developed a light-regulated molecule that could improve chemotherapy treatments by controlling the activity of anticancer agents.
Chemotherapy – the use of cytotoxic agents to kill the rapidly proliferating cells in tumors – is one of our main tools in the fight against cancer. However, its effectiveness and the body’s tolerance of it is often dramatically limited: it can affect healthy areas rather than just the cancerous ones, which causes side effects.
Researchers at IBEC and IDIBELL have developed a light-regulated molecule that could improve chemotherapy treatments by controlling the activity of anticancer agents.
Today Spain’s Severo Ochoa Centres of Excellence – including IBEC – and the María de Maeztu Units of Excellence are at the CNIO in Madrid for 100xCiencia.3, the annual event of the

IBEC group leader Eduard Torrents appeared on TV3’s Telenotícies on Monday night explaining his BiofilmChip project that has been funded with a CaixaImpulse grant.
IBEC researchers were in the limelight today at the awards ceremony for the “la Caixa” fellowships and grants for research and innovation calls.
Genetic Engineering & Biotechnology News (GEN), the flagship publication of the USA’s